

# IDEA Annual Review

## Summary 2015

December 16<sup>th</sup>, 2015

# IDEA Annual Review 2015


## Key conclusions




- Three years into IDEA, this science-based multi-stakeholder dialogue has arrived at QRA2, which now must be validated by implementation and monitoring of clinical fragrance allergy.
- The model has been built conservatively around the concept of a sensitization threshold and has undergone review by leading scientists.
- QRA2 needs to be presented in a more accessible format, which also takes into account the comments of the JRC and the SCCS.
- Further work is required:
  - To better address pre- and pro-haptens
  - To consider consumer/professional/occupational exposure to fragrance ingredients whatever their origin. This may require the inclusion of additional stakeholders.

# IDEA Annual Review 2015

## Key conclusions



- In principle QRA2 can be extended to other categories of substances that consumers are exposed to, but for each category of substances modifications may be needed and the usefulness must be validated by feedback from clinical data.
- Having been largely dependent on animal data, QRA now needs to transition to alternative methodologies.
- In starting the next phase of the IDEA Project, there are many critical issues to be addressed. The Annual Review meeting is extremely important in this regard.



**Thank you very much  
for your attention**

